2016-2020 Sales, Major Manufacturers, 2020-2021 Prices, 2021-2025 Outlook


DUBLIN, December 31, 2021 / PRNewswire / – The “Investigation report on from China Temozolomide market 2021-2025 “ the report was added to ResearchAndMarkets.com offer.

Research and Markets logo

The sales value of Temozolomide in the Chinese market has increased year on year from 2016 to 2019. Due to the impact of COVID-19 on all diagnostic and treatment departments of Chinese hospitals, the value of sales of Temozolomide in the Chinese market decreased to CNY 793 million in 2020 and Temozolomide’s CAGR in sales value from 2016 to 2020 is 9.04%.

Temozolomide is a second generation alkylating agent. It is an oral chemotherapy drug used to treat brain cancers such as adult malignant glioma and malignant melanoma. It was developed by Merck & Co., Inc. The drug was approved to enter the Chinese market under the trade name TEMODAL in 2007. By 2020, Temozolomide has been included in from China Class B medical insurance. There are many manufacturers in the Chinese market in 2020, of which Merck Sharp & Dohme Ltd is the main manufacturer.

The analyst expects that with the relief of COVID-19, the sales value of Temozolomide in the Chinese market will see restorative growth from 2021 to 2025. In addition, as the incidence of brain cancer primary increases, other cancers can cause secondary brain cancer.

Therefore, with the widespread use of digital electronic products and the increase in the incidence of other cancers, the incidence of brain cancer is also increasing year by year, the sales value and sales volume of Temozolomide for the treatment of brain cancer will continue to increase. .

At the same time, temozolomide has the characteristics of easily penetrating the blood-brain barrier and causing mild side effects. The analyst predicts that the sales value and sales volume of Temozolomide in the Chinese market may increase from 2021 to 2025.

Topics covered:

  • The impact of COVID-19 on from China Temozolomide market

  • Sales value of from China Temozolomide 2016-2020

  • competitive landscape of from China Temozolomide market

  • Temozolomide price in China

  • Temozolomide price in China by regions and manufacturers

  • Analysis of factors affecting the development of from China Temozolomide market

  • Perspective of from China Temozolomide market from 2021 to 2025

Main topics covered:

1 Relevant concepts of temozolomide
1.1 Indications for temozolomide
1.2 Development of Temozolomide in China
1.3 Government approval of temozolomide in China
1.4 The impact of COVID-19 on temozolomide sales in China

2 Sales of Temozolomide in China, 2016-2020
2.1 Sales value of temozolomide
2.1.1 Overall value of sales
2.1.2 Sales value by region
2.2 Temozolomide Sales Volume
2.2.1 Global sales volume
2.2.2 Sales Volume by Region
2.3 Sales of temozolomide by dosage form in China, 2016-2020
2.3.1 Injection
2.3.2 Analysis of other dosage forms

3 Major Manufacturers Analysis of Temozolomide in China in 2020
3.1 Major Manufacturers of Temozolomide Market Share Analysis
3.1.1 Market Share by Sales Value Survey
3.1.2 Market Share by Sales Volume Survey
3.2 Merck Sharp & Dohme Ltd
3.2.1 Company profile
3.2.2 Sales of TEMODAL (Temozolomide by Merck Sharp & Dohme Ltd) in China
3.3 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.
3.3.1 Company profile
3.3.2 Sales of Diqing (Temozolomide of Jiangsu Tasly Diyi Pharmaceutical Co., Ltd.) in China
3.4 Beijing Shuanglu Pharmaceutical Co., Ltd.
3.4.1 Company profile
3.4.2 Sales of Jiaoning (Beijing Shuanglu Pharmaceutical Co., Ltd.) Temozolomide in China
3.5 Schering-Plow Canada
3.5.1 Company Profile
3.5.2 Sales of TEMODAL (Temozolomide from Schering-Plow Canada) in China
3.6 Jiangsu Hengrui Medicine Company Ltd.
3.6.1 Company Profile
3.6.2 Sales of Temozolomide by Jiangsu Hengrui Medicine Company Ltd. in China

4 Prices of temozolomide for different manufacturers in China, 2020-2021
4.1 Merck Sharp & Dohme Ltd (TEMODAL)
4.2 Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (Diqing)
4.3 Beijing Shuanglu Pharmaceutical Co., Ltd. (Jiaoning)
4.4 Schering-Plow Canada (TEMODAL)
4.5 Jiangsu Hengrui Medicine Company Ltd.

5 China Drug Temozolomide Market Outlook, 2021-2025
5.1 Influential factors for the development of the Chinese temozolomide market
5.2 Market Size Forecast
5.3 Market Trend Forecast

Companies mentioned

  • Merck Sharp & Dohme Ltd (TEMODAL)

  • Jiangsu Tasly Diyi Pharmaceutical Co., Ltd. (Diqing)

  • Beijing Shuanglu Pharmaceutical Co., Ltd. (Jiaoning)

  • Schering-Plow Canada (TEMODAL)

  • Jiangsu Hengrui Medicine Company Ltd.

For more information on this report, visit https://www.researchandmarkets.com/r/sheueq

Media contact:

Research and markets
Laura Wood, senior
[email protected]

For EST office hours, call + 1-917-300-0470
For USA / CAN call toll free + 1-800-526-8630
For GMT office hours, call + 353-1-416-8900

US Fax: 646-607-1907
Fax (outside the United States): + 353-1-481-1716

Cision

Cision

Show original content:https://www.prnewswire.com/news-releases/china-temozolomide-market-report-2021-sales-2016-2020-major-manufacturers-2020-2021-prices-prospects-2021-2025-301452354.html

SOURCE Research and Markets


Comments are closed.